Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Bitwise Ethereum ETFBitwise Ethereum ETF Commences Operations and Reports Financial Results for 2024
PROKIDNEY CORP.ProKidney Reports $163.3 Million Net Loss for 2024, Increases R&D Spending
Ramaco Resources, Inc.Ramaco Resources Reports $11.19 Million Net Income for 2024, Revenue Declines 4%
TRANSCONTINENTAL REALTY INVESTORS INCTranscontinental Realty Reports Decrease in Net Income and Revenue for Fiscal Year 2024
Bakkt, Inc.Bakkt Holdings Reports $349M Revenue Surge and $103.4M Net Loss for 2024
AMERICAN REALTY INVESTORS INCAmerican Realty Investors Reports $14.7 Million Net Loss for Fiscal Year 2024
AlTi Global, Inc.AlTi Global Reports $174.3 Million Net Loss for 2024, Revenue Declines to $206.9 Million
GYRE THERAPEUTICS, INC.Gyre Therapeutics Reports $17.9M Net Income for 2024, Improved Profitability Amid Revenue Decline
AGENUS INCAgenus Inc. Reports $232.3 Million Net Loss for 2024, Decreased R&D Revenue
Akoya Biosciences, Inc.Akoya Biosciences Reports $81.7M Revenue in 2024, Faces Net Loss of $55.4M
OCULUS INC.Oculus Inc. Reports $327,360 Net Loss for Fiscal Year 2024, Seeks Additional Financing
KYNTRA BIO, INC.Fibrogen Reports 37% Revenue Decline to $29.6 Million for 2024
Sana Biotechnology, Inc.Sana Biotechnology Reports $266.76 Million Net Loss for 2024, Improved from Previous Year
ATAI Life Sciences N.V.ATAI Life Sciences Reports $149.3 Million Net Loss for Fiscal Year 2024
SANGAMO THERAPEUTICS, INCSangamo Therapeutics Reports $97.9 Million Net Loss and Decreased Revenues in 2024
Metagenomi Therapeutics, Inc.Metagenomi Reports $78.1 Million Net Loss for 2024, Highlights IPO and R&D Progress
CBAK Energy Technology, Inc.CBAK Energy Technology Reports $176.6M Revenue and $9.6M Net Income for Fiscal Year 2024
FVCBankcorp, Inc.FVCBankcorp Reports Significant Increase in Net Income to $15.1 Million for Fiscal Year 2024
Cannabist Co Holdings Inc.The Cannabist Company Reports $105.9 Million Net Loss for Fiscal Year 2024
COGNITION THERAPEUTICS INCCognition Therapeutics Reports $33.97 Million Net Loss for 2024, Concludes Phase 2 MAGNIFY Study
MSC INCOME FUND, INC.MSC Income Fund Reports $56.5M Net Increase in Assets for 2024, NYSE Listing Planned
ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Reports $8M Net Income for 2024, Driven by Neffy Launch
Avalo Therapeutics, Inc.Avalo Therapeutics Reports $35.1 Million Net Loss for 2024, Highlights AlmataBio Acquisition
Invivyd, Inc.Invivyd Reports $169.9 Million Net Loss for 2024, Highlights PEMGARDA Sales
Monte Rosa Therapeutics, Inc.Monte Rosa Therapeutics Reports $72.7 Million Net Loss for 2024, Highlights Collaboration Revenue Growth